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Running Title:  Glucocorticoid Crosstalk with Hedgehog Signaling 
Summary 
The Hedgehog signaling pathway is linked to a variety of diseases, notably a range of cancers. 
The first generation of drug screens identified Smoothened (Smo), a membrane protein essential 
for signaling, as an attractive drug target. Smo localizes to the primary cilium upon pathway 
activation, and this transition is critical for the response to Hedgehog ligands. In a high content 
screen directly monitoring Smo distribution in Hedgehog responsive cells, we identified different 
glucocorticoids as specific modulators of Smo ciliary accumulation. One class promoted Smo 
accumulation, conferring cellular hypersensitivity to Hedgehog stimulation. In contrast, a second 
class inhibited Smo ciliary localization and signaling activity by both wildtype Smo, and mutant 
forms  of  Smo,  SmoM2  and  SmoD473H,  that  are  refractory  to  previously  identified  Smo 
antagonists.  These  findings  point  to  the  potential  for  developing  glucocorticoid-based 
pharmacological modulation of Smo signaling to treat mutated drug-resistant forms of Smo, an 
emerging  problem  in  long-term  cancer  therapy.  They  also  raise  a  concern  about  potential 
crosstalk of glucocorticoid drugs in the Hedgehog pathway, if therapeutic administration exceeds 
levels associated with on-target transcriptional mechanisms of glucocorticoid action.   
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Highlights    
 Screened 5,672 compounds from annotated compound libraries for their ability to 
modulate Smo movement to the primary cilium 
 Identified a large class of glucocorticoids such as fluocinolone acetonide (FA) that have 
the unusual property of promoting Smo accumulation in the primary cilium, whilst not 
substantially activating a transcriptional response – a chemical separation of what are 
likely distinct mechanisms of Smo activation 
 Demonstrated that these compounds sensitize cells to Hh input 
 Provided evidence that high dose off target effects of glucocorticoids can potentially 
modify the efficacy of current pathway antagonists in clinical trials for anti-cancer 
activities 
 Extended SAR on glucocorticoid scaffold identifies pathway inhibitors, which, 
importantly, show equal efficacy in inhibiting Smo mutant forms resistant to current 
therapeutic lead compounds 
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E-TOC Paragraph 
 Using  a  new  high  content  screen,  a  number  of  glucocorticoid  drugs  were  identified 
promoting translocation of Smoothened to the primary cilium, a cell organelle where Hedgehog 
signaling occurs. Selective characterization of potent hits discovered such glucorticoids lead to 
sensitized cell response to Hedgehog input and  less effective inhibition by Smo antagonists. 
Further,  an  extended  study  of  structure-activity  relationship  identified  Budesonide  as  an 
antagonist  of  Smoothened  ciliary  translocation,  which  displayed  equal  efficacy  in  inhibiting 
wildtype and mutant Smoothened that are refractory to current therapeutic lead compounds. 
 
 
 
 
Introduction    
    The  Hedgehog  (Hh)  pathway  is  one  of  the  central  pathways  of  animal  development,  and 
deregulated  pathway  activity  underlies  a  multitude  of  diseases,  notably  a  variety  of  cancers 
(Rubin  and  de  Sauvage,  2006).    Activating  mutations  in  Hh  pathway  components  are  cell 
intrinsic causal factors in cancers linked to Gorlin syndrome, medulloblastoma (MB), basal cell 
carcinoma (BCC), and rhabdomyosarcoma (RMS). In addition, paracrine Hh signaling-based 
modulation of the tumor microenvironment is thought to play a wider role in the support of a 
number  of  other  malignancies  including  those  of  the  breast,  lung,  liver,  stomach,  pancreas, 
prostate, and colon (Yauch, et al., 2008).  Hh signaling is also linked to medically beneficial 
actions such as the promotion of stem/progenitor cell proliferation that may enable regenerative 5 
 
therapies. Considerable clinical interest has developed about the mechanisms of Hh pathway 
action and the identification of drugs that can modulate pathway activity. 
   Smoothened (Smo), a seven-pass transmembrane protein, has emerged as a predominant target 
in screens for small-molecule pathway modulators. Smo is essential for all Hh signaling(Zhang, 
et al., 2001). All 7 drugs in clinical trials for Hh targeted cancer therapy act directly on Smo to 
inhibit Hh signaling(Tremblay, et al., 2010). Among these, GDC0449 (also known as RG3616 or 
Vismodegib),  was  recently  approved  by  the  US  Food  and  Drug  Administration(FDA)  for 
indication  of  advanced  BBC(Allison,  2012).  On  the  other  hand,  it  was  reported  that 
administration  of  at  least  two  clinical  Smo  antagonists  (GDC0449  and  LDE225)  resulted  in 
cancer relapse in human and/or mouse in part due to emergence of drug resistant mutations of 
Smo, which highlighted an unmet medical need for next generation Smo antagonists that can 
circumvent such mutations (Buonamici, et al., 2010; Yauch, et al., 2009). Smo regulation is quite 
unusual. Hh binding to its receptor Patched-1 (Ptch1) counters Ptch1 mediated inhibition of Smo, 
enabling Smo-dependent activation of a Gli-based transcriptional response (Rohatgi, et al., 2007). 
These events correlate with, and are critically linked to, the primary cilium (PC), a tubulin-based 
cell extension present on most vertebrate cells(Goetz and Anderson, 2010).After binding Hh, 
Ptch1  moves  from  the  PC  while  Smo  accumulates  on  the  ciliary  axoneme.  Though  the 
mechanistic details are unclear, Smo action at the PC is essential for pathway activation(Han, et 
al., 2009; Wong, et al., 2009), and this cellular translocation presents an opportunity for novel 
drug development.  
    Here we report on a high content screen (HCS) to identify small molecules that modulate Smo 
accumulation at the PC. Most strikingly, we identified a large number of glucocorticoids (GC), 
several of which are in clinical use, that induce this activity. Surprisingly, these compounds fail 6 
 
to trigger robust pathway activation; instead, they sensitize cells to Hh ligand input and impair 
pathway inhibition by co-administered pharmacological antagonists of Smo signaling. In contrast, 
anther steroid, Budesonide , inhibits Smo ciliary translocation and Hh signaling, synergizing 
with GDC0449, a Smo antagonist under clinical evaluation.  Importantly, Budesonide acts 
similarly on wildtype Smo, and mutant forms refractory to other Smo antagonists, SmoM2 and 
SmoD473H (Xie, et al., 1998; Yauch, et al., 2009). These findings have important ramifications 
for the design of new therapeutic approaches to treat cancers whose growth can be modulated by 
Smo activation, and potential implications for off-target crosstalk of glucocorticoid drugs in the 
Hedgehog signaling pathway.  
 
Results 
Development of a high content screen to identify agonists of Smo ciliary accumulation.   
  To gain a more comprehensive view of the Hh pathway at early stages of drug development, we 
developed and validated a novel High Content Screening (HCS) method based directly on Smo 
translocation to the PC(Wang, et al., 2012). Herein we report our findings while using the 
method to identify agonists of Smo ciliary accumulation. An EGFP tagged form of human Smo 
was introduced into Hh responsive NIH3T3 cells(Wang, et al., 2009) (Fig. S1 A) to generate a 
clonal cell line in which Hh-dependent accumulation of Smo::EGFP in the PC mirrored 
movement of endogenous Smo(Wang, et al., 2009). An Inversin(Ivs)::tagRFPT expression 
cassette provided a constitutive, independent PC marker (Watanabe, et al., 2003).  
   Custom algorithms were developed to perform quantitative multi-parametric image 
analyses(Wang, et al., 2012). Robust dose dependent responses were observed upon treatment 
with several known small molecule modulators of Smo: the agonist SAG and the antagonist 7 
 
cyclopamine (Cyc), both of which directly bind Smo, and forskolin (FKL), whose stimulatory 
action on protein kinase A inhibits Smo signaling (Fig. S1 A-F). Despite the fact that Cyc and 
SAG physically interact with Smo in a competitive fashion suggesting a common binding 
mechanism, and that both induce ciliary accumulation, Cyc bound Smo is inactive. Thus, 
accumulation within the primary cilium appears to be essential but not sufficient for downstream 
activation of the Hh pathway. In contrast, FKL likely induce Smo ciliary accumulation indirectly 
potentially by accelerating anterograde intraflagellar transport (Besschetnova, et al., 2010). A 
better understanding awaits a clearer picture of the cellular trafficking processes. As a 
demonstration of the assay’s ability to detect local changes within the PC, elongation of the PC 
on FKL treatment was detected as an expanded Ivs+ domain (last panel in Fig. S1 F), consistent 
with a recent report(Besschetnova, et al., 2010). 
 
Screening results 
We conducted a screen with a library consisting of 5,672 compounds with annotated activities, 
including FDA approved drugs and drug candidates in preclinical or clinical development. 
Representative examples of plates including small-molecule control wells are shown for the 
analysis (Fig. S1 G). Z-prime scores(Zhang, et al., 1999) consistently >0.4 indicate  a reasonable 
reliability of the primary screen.  
    Approximately 60 compounds in 15 distinct chemical classes were confirmed to induce Smo 
accumulation at the PC, after rigorous assessment of the dose-response curves for primary hits. 
As expected, these comprised both pathway agonists and antagonists. For example, LY 294002, 
an inhibitor of phosphatidylinositol 3-kinase (PI3K) (Vlahos, et al., 1994), induces Smo ciliary 
accumulation, but inhibits Hh signaling (Fig. S1 H-K). The PI3K pathway is important in a 8 
 
variety of cancer types and may intersect with the Hh pathway in tumorigenesis 
(Hambardzumyan, et al., 2008). In combination treatment, a PI3K inhibitor and a Smo 
antagonist delayed the onset of drug resistance in a mouse model of medulloblastoma 
(Buonamici, et al., 2010; Dijkgraaf, et al., 2011). PI3K action has also been linked to the 
regulation of Gli proteins through the Akt pathway (Riobo, et al., 2006).  These data suggest that 
PI3K may act at multiple levels in Hh signaling. 
Strikingly, the most predominant chemical class identified comprised naturally occurring and 
synthetic glucocorticoids (GC), several of which are widely used as anti-inflammatory agents in 
the clinic (Fig. 1 A-B; Fig. S1 L) (Sommer and Ray, 2008). Interestingly, a recent screen 
examining β-arrestin aggregation identified an overlap with a subset of these compounds, 
lending additional support to a GC intersection in Smo-directed Hedgehog signaling, but also 
raising the possibility of alternative mechanisms (Wang, et al., 2010). Structure-activity 
relationship (SAR) analysis suggests that fluorine at position 9, a ketal at positions 16 and 17, 
and protonation at position 11 significantly enhance the potency of this class of compounds in 
directing Smo accumulation to the PC (Fig. 1 C). 
 
GCs accumulate Smo in the PC without activating the Hh pathway. 
To investigate in more detail the consequences of GC-induced Smo accumulation in the PC, and 
to obtain mechanistic insights into GC action in the Hh pathway, we first chose one compound in 
clinical use, fluocinolone acetonide (FA). FA displays an EC50 of around 5 µ M for 
accumulation of Smo in the PC; in addition, no obvious cytotoxic effects are observed in vitro at 
much higher doses (up to 200 µM ; Fig. 1 B and D, Fig. S1 M). Localization of an inversin-based 
PC reporter and other PC markers including Arl13b, acetylated tubulin, and detyrosinated α- 9 
 
tubulin (glu-tub) were unaltered in response to FA (Fig. 1D; Fig. S1 M and N)(Caspary, et al., 
2007; Schroder, et al., 2007; Watanabe, et al., 2003). Further, no change was detected in the 
activity of a Wnt-signaling reporter in response to FA concentrations that modify Smo 
distribution (Fig. S1 O). Together these data suggest that FA’s effects in this assay are specific to 
the Hh pathway. 
The accumulation of Smo in the PC is thought to be essential for transcriptional activation of 
the Hh pathway (Kim, et al., 2009; Rohatgi, et al., 2007). However, we observed a marked 
disparity between FA-induced Smo accumulation in the PC and Hh pathway activation in 
transcription reporter assays. At low levels of FA that effectively promote Smo accumulation in 
the PC (10µ M), no pathway activation was observed. Higher concentrations (>50 µ M) invoked a 
weak transcriptional response measurable in a Gli-luciferase reporter assay (4 fold versus 25 fold 
for 1µ M of the Smo agonist SAG in the same assay (data not shown)), and on quantitative 
reverse transcription–polymerase chain reaction (qRT-PCR) measurement of Hedgehog target 
gene expression (Ptch1 and Gli1; Fig. 2A-B). The EC50 for weak transcriptional activation 
(>50µM ) was 10 fold higher than that of FA-induced accumulation of Smo within the PC.  
FA induces hypersensitivity to Hh pathway stimulation. 
The effects of FA resemble over-expression of Smo in that constitutive accumulation of wild-
type Smo within the PC only results in weak pathway activation (Fig. S2 A). Ciliary 
accumulation of Smo sensitizes cells to subsequent Sonic hedgehog (Shh) ligand input, raising 
the possibility that FA-driven Smo accumulation may sensitize Hh responsive cells. Indeed, co-
stimulation of cells with 10µ M FA results in a dose-dependent enhancement of a Shh-induced 
transcriptional response (Fig. 2 C-D). Furthermore, this effect was measurable after prolonged 
withdrawal of FA; cells treated for 24 hours with FA followed by compound withdrawal prior to 10 
 
Shh addition showed a higher induction of pathway activity than DMSO treated controls (Fig. 2 
E-F).  The EC50 of a FA induced response to priming is approximately 4µ M, in good agreement 
with the dose required for efficient accumulation of Smo in the PC (Fig. 1 B). Smo turnover in 
the PC is relatively slow after Shh-invoked pathway activation(Wang, et al., 2009), or compound 
withdrawal (Fig. S2 B-C), providing a potential explanation for a FA induced pathway priming 
effect.  FA treatment showed no effect on Wnt pathway activity (Fig. S1 O), consistent with Hh 
pathway specificity.   
 
FA may regulate Smo by direct binding. 
To determine whether FA interacts with Smo, we performed a competition assay with Bodipy-
Cyc. Cyc binds Smo directly (Chen, et al., 2002) and its fluorescent analog, Bodipy-Cyc, shows 
strong Smo-dependent fluorescence within cells over-producing Smo (identified by co-
expression of a nuclear localized tagRFP-T, Fig. 2 G-H).  An oncogenic mutation within the 7
th 
transmembrane domain (SmoM2, also named SmoA1, Fig. 2 H-I) (Chen, et al., 2002), and a 
recently described drug resistance mutation within the 6
th transmembrane domain (SMOD473H) 
significantly impair Cyc binding to Smo, suggesting that these are critical sites for chemical 
interaction (Yauch, et al., 2009).   
FA displayed a dose-dependent competition of Bodipy-Cyc binding to wild-type Smo, similar to 
other small molecules that directly bind Smo (SAG, and GDC0449), or that likely interact 
directly with Smo based on similar competition assays (SANT-1) (Fig.2 H-I) (Chen, et al., 2002; 
Chen, et al., 2002; Frank-Kamenetsky, et al., 2002; Yauch, et al., 2009).  In contrast, FKL 
induces Smo accumulation in the PC but does not compete with Bodipy-Cyc, reflecting an 
indirect action through its protein kinase A target (Milenkovic, et al., 2009; Wilson, et al., 2009). 11 
 
Weak pathway activation induced by FA was attenuated by Smo antagonists (Fig. 2 A) and 
depended on endogenous Smo as activation was not observed in fibroblasts lacking Smo activity 
(Fig.S2D). SANT-1 and GDC0449 inhibit FA promoted accumulation of Smo in the PC (Fig. S2 
E-F). Collectively, these data support a direct interaction between FA and Smo. 
 
Antagonistic drug-drug interactions between FA and Smo antagonists 
Considering that GCs and various Hh pathway antagonists may share a common Smo target, 
and GCs are widely used to suppress inflammation in conjunction with cancer therapy, we next 
asked whether we could observe a potential GC crosstalk with Smo antagonists in cell culture 
assays. Hh pathway inhibition by GDC0449, Cyc and SANT-1, as measured by both Gli-
luciferase induction (Fig. 3A and Fig. S3) and Smo ciliary localization (Fig.3 B-C and Fig. S3), 
was dramatically reduced in vitro in the presence of FA. Thus, FA co-treatment leads to a drug-
dependent alteration of cellular response to chemical inhibitors of Smo. This may occur through 
competition, or the requirement for a higher level of GDC-0449 to inhibit Hh-driven pathway 
activity in the presence of GC, but the outcome resembles the genetic resistance seen with a 
dominant active Smo mutation (SmoM2) (Fig. 3A). 
 
Common properties of FA and TA in modulating Smo localization and Hh pathway 
activity. 
We next assessed whether the observations for FA were replicated by a second clinically 
approved GC, Triamcinolone Acetonide (TA). TA was slightly more potent than FA in Smo 
ciliary translocation assay (Fig.1B). Similar to FA, TA only evoked a Gli-mediated 
transcriptional response at much higher doses than those that induced Smo ciliary accumulation, 
although the Hh pathway was activated to higher levels than measured on FA treatment 12 
 
(Fig.S4A). No activation was observed in Smo-/- embryonic fibroblast cells as expected 
(Fig.S2D). Further, at 10µM  TA enhanced the response to Hh ligand (Fig.S4B), a dose that does 
not sufficient to induce ligand-independent pathway activity (Fig.S4A). TA also displayed a dose 
dependent competition with Bodipy-Cyc for binding to Smo (Fig.S4C-D). More importantly, 
10µM  TA induced a dose-response shift for GDC0449 mediated inhibition of Hh pathway 
activity, and Smo ciliary accumulation induced by ligand treatment (Fig. S4E-G). Taken together, 
our results indicate that these, and possibly other GCs that alter Smo localization share broadly 
similar biological properties but further work will be required to examine the extensive set of 
compounds identified in our study. 
 
ex vivo studies of FA with Ptch1+/- CGNPs 
   To further explore FA actions, we isolated cerebellar granule neuron precursors (CGNPs) from 
Ptch1+/- neonates. Proliferation of CGNP is Shh-dependent and Ptch1 heterozygosity 
predisposes both mice and humans to develop CGNP-derived medulloblastoma (Schuller, et al., 
2008). Consistent with results on Hh pathway activation in NIH3T3 cells, only very high doses 
of FA (120µM) elevated the number of proliferative, phospho-histone H3 (pH3) positive GCNPs 
(Fig. 4 A-B).  However, a lower dose of FA (10µM) markedly enhanced Shh-driven CGNP 
proliferation (Fig. 4 C-D). Further, co-administration of FA(10µ M), with the Smo antagonist 
GDC0449, impaired GDC0449 inhibition of Shh-stimulated GCNP proliferation  (Fig. 4 E-F). 
 
GC inhibitors of Smo accumulation to the PC and of Smo signaling.  
    While a large number of GCs promote Smo ciliary accumulation, secondary assays of small 
molecules sharing the core GC scaffold identified two inhibitory GCs: Budesonide (Bud) and 13 
 
Ciclesonide (Cic) (Fig. 5 A-C; Fig. S5 A-C). When compared with Smo promoting GCs, Bud 
and Cic are distinguished by bulky hydrophobic groups at positions 16 and 17 (Fig. 1; Fig. S1 L; 
Fig.5A; Fig. S5 A).  In contrast to FA and TA, Bud had no pathway inducing activity, nor did 
Bud induce a hypersensitive response to Hh ligand (Fig. 2 A-F; Fig. 5 D), reinforcing the 
association of hyper-responsiveness to Smo ciliary accumulation activity.  As expected from the 
inhibition of Smo accumulation in the PC, Bud and Cic inhibited Shh dependent activation of a 
Gli-reporter (Fig. 5 E and Fig. S5 D). Further, Bud attenuated Smo ciliary accumulation and 
pathway activation by SAG (Fig. 5 E; Fig. S5 E-F), and also suppressed Cyc induced Smo 
accumulation to the PC (Fig. S5 E-F). Bud treatment showed no effect on Wnt pathway activity 
(Fig. S5 G), consistent with a specific modulation of Hh signaling outside of its GC activity.   
 
Bud inhibits ciliary localization and signaling of drug resistant mutants of Smo. 
SmoM2 encodes a dominant active Smo variant identified in a human cancer that is resistant 
to inhibition by available Smo antagonists at concentrations that completely suppressed wildtype 
Smo activity (Fig. S5 H-K)(Xie, et al., 1998). Unexpectedly, both Bud and Cic attenuated 
SmoM2 ciliary localization, and downstream pathway activity, as effectively as wildtype Smo 
(Fig. 5 F-H; Fig. S5 L-M). Bud and Cic did not disrupt ciliary structure or ciliary trafficking: 
acetylated-tubulin (acet-tub), Ivs::tagRFPT, and Arl13b::tagRFPT within the PC were unaltered 
on treatment (Fig. S5 N-R).     
The emergence of a drug resistant form of Smo with a D473H mutation was reported in a MB 
patient during treatment with GDC0449. The appearance of this mutation associated with a re-
emergence of the tumor (Yauch, et al., 2009). This finding has triggered a search for antagonists 
that effectively inhibit the activity of both wildtype and mutant forms of Smo (Dijkgraaf, et al., 14 
 
2011; Kim, et al., 2010; Tao, et al., 2011). We examined Bud and GDC0449 in parallel for their 
inhibition of Hh induced SmoD473H activity, and the corresponding ciliary localization. Smo-/- 
MEF cells were transfected independently with wildtype and D473H mutant forms of Smo. Both 
forms rescued the cell’s response to Hh ligand (Fig.S5S). As expected, the D473H mutation 
conferred a dramatic resistance to GDC0449’s inhibitory action on both Hh pathway activity and 
Smo ciliary localization (Fig. S5T-V).  In contrast, Bud showed similar efficacies in inhibiting 
wildtype Smo and SmoD473H activity in both assays (Fig.5I-K). 
To examine the site of Bud action in the Hh pathway, we examined Hh signaling activity 
following removal of suppressor of Fused (suFU) activity, a Gli repressor functioning 
downstream of Smo. Distinct from GANT61(Lauth, et al., 2007), Bud failed to suppress ligand-
independent Hh pathway activity induced by loss of suFU function (Fig. 5L). Together these data 
suggest that Bud may act at the level of Smo but through a different mechanism than other Smo-
interacting antagonists including SANT-1, Cyc, and GDC0449, and also distinct from FA and 
SAG. Consistent with a unique inhibitory action, Bud failed to compete with Bodipy-Cyc even at 
levels well above the inhibitory maximum (100 µM; Fig. 5 M-N). Further, whereas FA competed 
with GDC0449 to suppress effective pathway inhibition (Fig. 3), Bud enhanced GDC0449's 
activity to block Smo accumulation at the PC and Hh pathway inhibition (Fig. 6). 
 
Discussion 
     The interaction of GCs with the Hh pathway leads to several important observations: First, 
all small molecules that induce ligand-independent Smo accumulation to the PC characterized to 
date either activate or inhibit Smo activity. Agonists include SAG and purmorphamine (Chen, et 
al., 2002; Frank-Kamenetsky, et al., 2002; Sinha and Chen, 2006). Cyc though an antagonist also 15 
 
induces Smo transolcation to the PC(Rohatgi, et al., 2009; Wang, et al., 2009; Wilson, et al., 
2009). Several lines of evidence indicate that whereas Smo accumulation in the PC is essential 
for signaling, accumulation is not sufficient, with additional ligand-dependent actions being 
required to generate an active form of Smo (Rohatgi, et al., 2009; Wang, et al., 2009; Watanabe, 
et al., 2003; Wilson, et al., 2009). Together, our data suggest that many GCs can function in a 
novel mechanism that synergizes with Hh-ligand-directed signaling by promoting accumulation 
of Smo within the primary cilium.  The synergistic effect might result from bypassing a Ptch1-
mediated "barrier" for Smo entry to the primary cilium facilitating the activation of Smo, which 
appears to be restricted to this organelle. The mechanism of divergent pharmacological 
modulations of Smo ciliary translocation and its activity is not understood. A recent report 
suggested that Smo phosphorylation plays a role in its ciliary translocation and activation (Chen, 
et al., 2011). Further study of small molecule directed changes in Smo phosphorylation will 
enhance our understanding of the significance of phosphorylation in localization and activity.  
 Second, the finding of a potential effect of Smo promoting GCs in modulating the Hh 
response highlights the value of a “direct target screen” focusing on critical parameters of target 
action. To date most small molecule Hh pathway modulators have been identified through “end-
point” transcriptional assays. However, because of their modest effects on transcription, GC 
interactions are not readily detected with this screening approach. Such disparity suggests that 
the mechanism of pharmacological induction of Smo accumulation to the primary cilium and its 
retention there is divergent from that of its activation. 
 Third, the dose of GC required to modify Smo localization (EC50s>1µ M) is significantly 
higher than that required to directly modulate GC receptor-based transcriptional responses 
(EC50s  <10 nM or lower (Johnson, 1998)). Thus, we believe GC’s likely act directly on Smo at 16 
 
high concentrations, and not indirectly through a nuclear hormone receptor triggered 
transcriptional regulatory action.  
Fourth, naturally occurring hydrocortisone and cortisone show different potencies in 
accumulating Smo to the PC (Fig. 1 A and B). 11β-hydroxysteroid dehydrogenase type 2 
(HSD11β2), an enzyme that transforms hydrocortisone into cortisone, is up-regulated by Hh 
signaling in CGNPs (Heine and Rowitch, 2009), whereas HSD11β1, an enzyme that mainly 
catalyzes the reverse reaction, was recently discovered as a target gene for Hh signaling in 
prostate cancer tissue (Shaw, et al., 2009). Taken together, these findings suggest potential 
feedback mechanisms linking the Hh transcriptional output to steroid regulation of Smo action.  
Fifth, inflammation and cancer are linked, necessitating combinatorial therapies to treat both 
aspects of disease (Mantovani, et al., 2008). To this end, GCs are frequently co-administered to 
patients receiving anti-cancer therapies. However, GCs are reported to enhance cancers of the 
breast (Sui, et al., 2006), colon (Zhang, et al., 2006), lung (Herr, et al., 2003), ovary (Sui, et al., 
2006; Zhang, et al., 2006), and pancreas (Zhang, et al., 2006), and to increase the metastatic 
potential of breast cancer (Sherlock and Hartmann, 1962). Amongst these are glucocorticoids 
that promote Smo ciliary accumulation in the current study. Further, FA is reported to act as a 
tumor promoter in the skin(Fukao, et al., 1988). Our studies also raise the possibility of high 
dosing of glucocorticoids leading to off-target action of glucocorticoid agents in the Hh pathway, 
modifying therapeutic outcome: for example, in Hh-antagonist-directed cancer therapy. Whether 
an effective dose for GC drug-mediated crosstalk is reached during therapeutic administration is 
not clear, but the pharmacokinetics of certain GC drugs in human patients may warrant further 
investigation.  For example, a peak plasma concentration of Dexamethasone, a broadly used GC 
in cancer patients, has been reported at  >10µ M after a single high dose (Brady, et al., 1987), 17 
 
which falls in the range where significant Smo cilial accumulation occurs in vitro (data not 
shown). Long-term systematic treatment, common in cancer therapy, might result in longer 
exposure to higher concentrations. Further, high dose of glucocorticoids are given to preterm 
infants to accelerate maturation of the lungs. Whether glucocorticoids in this scenario may 
influence developmental Hh signaling is not known. 
Sixth, our data suggest that most GCs likely share a similar interaction site with a broad range 
of agonists and antagonists including SAG, GDC0449, SANT-1, and Cyc, or modify Smo on 
binding to block access to this binding region. In contrast, Bud-like GCs do not compete with 
other Smo antagonists. Further, Bud works equally well inhibiting wildtype Smo and mutant 
forms of Smo refractory to clinically active inhibitory compounds. Thus, it may act more like an 
allosteric regulator of Smo activity. Interestingly, GDC0449 resistant SmoD473H can be readily 
inhibited by it’s the related benzimidazole HhAntag (Dijkgraaf, et al., 2011). Subsequent efforts 
to improve Bud potency should keep in mind the clinical imperative of pan-inhibition of Smo 
mutant forms. Collectively, our findings highlight the potential to develop new drugs around a 
GC scaffold that may synergize with compounds currently undergoing clinical development to 
enhance anti-Hh-based cancer therapies and may also reveal more about the ways in which Smo 
trafficking and activity are regulated.   
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Materials and Methods 
Cell Culture 
    NIH/3T3 cells were maintained in DMEM containing 10%(v/v) calf serum, penicillin, 
streptomycin, and L-glutamine. HEK293, L, cos7 , and suFU-/- mouse embryonic fibroblast cells 
were maintained in DMEM containing 10%(v/v) fetal bovine serum, penicillin, streptomycin, 
and L-glutamine. Smo::EGFP and Ivs:: tagRFPT were cloned into pBabe retroviral constructs. 
Smo::EGFP/Ivs::tagRFPT stable cell lines was generated through viral infecting NIH/3T3 cells 
according to the procedure described previously(Wang, et al., 2009). A ShhLightII cell line 
(ATCC) was used for Gli-luciferase reporter assays. This line contains a stably integrated Gli-
responsive firefly luciferase reporter and a constitutive Renilla luciferase expression construct 
(Taipale, et al., 2000). A subclone of this cell line was created expressing a stably integrated 19 
 
SmoM2 expression construct. Shh conditioned medium was collected from cos7 cells transfected 
with an expression construct encoding the amino terminal 19kDa signaling peptide of Shh and 
used at 13.7(± 3.0)nM unless stated otherwise. Control conditioned medium was collected from 
cos7 cells transfected with an empty plasmid. Wnt3a conditioned medium was collected from an 
L cell line stably expressing a Wnt3a expression construct. Control conditioned medium was 
collected from wild-type L cells. All conditioned medium were diluted 1:10 prior to assay. 
Reagents 
    Chemical libraries screening utilized the Library of Pharmacologically Active Compounds 
(LOPAC, Sigma-Aldrich), the Spectrum Collection (Microsource Discovery Systems), and the 
Prestwick Chemical Library (Prestwick Chemical), along with a custom collection of additional 
biologically annotated chemistries absent from the above pre-plated reference collections. 
Glucocorticoids, cyclopamine, forskolin, mouse monoclonal anti-acetylated tubulin antibody for 
follow-up studies were purchased from Sigma. SAG was purchased from Axxora Platform. 
SANT-1 was obtained from Tocris Biosciences. GDC0449 was purchased from Selleck 
Chemicals. BODIPY-cyclopamine was purchased from Toronto Research Chemicals. All small 
molecule stock solutions were prepared by dissolving in DMSO at 1 or 10 mM and stored at -
20
OC. Mouse recombinant ShhN purified protein (IIShhN) was a gift from Dr. Pepinsky (Biogen 
Inc). Rabbit polyclonal anti-detyrosinated α-tubulin (Glu-tub) was from Chemicon, Mouse 
monoclonal anti-Arl13b antibody was from Antibody Incorporated. Secondary antibodies were 
from Life Technologies. Transfection was performed using Fugene6 or Fugene HD (Roche). 
 
 
Imaging Assays 
    Cells were cultured and treated in 384-well imaging plate precoated with poly-D-Lysine 
(Greiner Bio-one) ,  fixed with 4% paraformaldehyde (Electron Microscopy Sciences) , and 20 
 
stained with Hoechst(Life Technologies). Immunofluorescence staining was conducted with 
standard procedures when necessary. Images were collected using Opera High Content 
Screening System (Perkin Elmer). ActivityBase (IDBS), Pipeline Pilot (Accelrys), Excel 
(Microsoft), and Prism (GraphPad) were used for high content screening data management and 
analysis. Acapella 2.0 software (Evotec Technologies/PerkinElmer) was used to perform multi-
parametric image quantification. All the comparative images were scanned with identical 
microscopic setting and analyzed with the same input parameters. 
Hh and Wnt activity assays 
    ShhLightII cells and SmoM2/LightII cells were cultured and treated in 96 well assay plates 
(Corning) and incubated with Duo-Glo luciferase substrates (Promega) to sequentially measure 
firefly and renilla luciferase activity. Smo, or GFP, expression plasmids were co-transfected into 
3T3 cells together with a Gli-responsive firefly reporter and a TK-renilla luciferase reporter 
contruct to monitor effects of Smo overexpression. Co-transfection of the two reporter constructs 
was conducted in assays measuring Hh pathway activity in suFU-/- cells. Wnt activity was 
measured following co-transfection of a Top-flash and renilla luciferase reporter. In both Hh and 
Wnt activity assays, renilla luciferase reporter activity, or mass of protein, was used to normalize 
expression values. Luciferase signal was read by TopCount NX  Microplate Scintillation and 
Luminescence Counter(Perkin Elmer).  Quantitative PCR probes for Ptch1, Gli1, and β-actin 
were purchased from Applied Biosystems.  Reactions and measurements were performed using 
on an Applied Biosystems 7900HT at Harvard FAS Center of System Biology. β-actin was used 
to normalize Ptch1 and Gli1 values. 
Bodipy-Cyclopamine Competition Assays 21 
 
    Cos7 cells were transfected with a plasmid that co-expresses Smo and a nuclear localized 
tagRFPT marker (pCIT-Smo).  The empty parental construct (pCIT) and a construct that co-
express SmoM2 were used as controls to assess specificity and background signal.  Three days 
after transfection, cells were incubated with 5nM Bodipy-cyclopamine, with or without 
additional compounds, for 1 hour at 37
OC.  Cells were then fixed and stained with Hoechst. 
Images were collected with the Opera High Content Screen System. Fluorescence values were 
assessed in transfected cells (red nuclei) with a program developed by the authors using Acapella 
2.0 software. All of images were scanned with identical microscopic setting and analyzed with 
the same input parameters. 
CGNP proliferation Assays 
    CGNP primary cells were isolated from P7 Ptch1+/- mice as previously reported(Chan, et al., 
2009).  Cells were seeded in poly-D-lysine coated imaging plates (Greiner Bio-one), treatments 
were applied 2 hours thereafter and last for 36 hours. Cells then were fixed with 4% 
paraformaldehyde (Electron Microscopy Sciences) , and stained with anti-pH3 antibody(Upstate; 
1:100) followed by a secondary antibody(Invitrogen) and Hoechst(Invitrogen). Images were 
collected and cell proliferation quantified with a program developed by the authors utilizing 
Acapella 2.0 software. All of the images in each experiment were collected with identical 
microscopic settings and analyzed with identical input parameters. 
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Figure Legends: 
 
Fig.1. Glucocorticoids induce Smo accumulation at the primary cilium. (A) Structures of 10 
representative naturally occurring and synthetic GCs (names in bold). (B) Related dose response 25 
 
curves for accumulation of Smo in the PC using the subset of GCs indicated in (A). The mean 
(± S.D.) was calculated for four replicates analyzing several hundred cells in each sample. (C) 
Key positions correlating with Smo accumulation activity in the GC scaffold are highlighted in 
red. (D) Representative images of dose-dependent accumulation of Smo at the PC in response to 
stimulation by a synthetic GC, fluocinolone acetonide (FA). Scale bar: 10µm.  
 
Fig.2. FA sensitizes cells to Hh stimulation and competes with Cyc binding to Smo (A) Modest 
but significant activation of the Hh pathway at high doses of FA, measured by a Gli responsive 
luciferase reporter activity in NIH/3T3 cells. FA action is blocked by Smo antagonists SANT-1 
and Cyc. * P < 0.0001 (t-test), comparing with DMSO, FA+SANT-1, or FA+Cyc. (B) FA up-
regulates the expression of Hh target genes Ptch1 and Gli1 in NIH/3T3 cells. #P<0.02 (t-test) (C-
D) Measurement of Hh pathway activity in cells treated simultaneously with a fixed 
concentration of FA and different concentrations of Shh ligand (C), or with a fixed concentration 
of Shh ligand, and different concentrations of FA (D). Treatment with Shh ligand and DMSO 
were used for comparison. (E) Measurement of Hh pathway activity after stimulation with 
various concentrations of Shh ligand following priming treatments with 10 µ M FA (red curve). 
DMSO prime treatments (blue curve) were used for comparison. (F) Measurement of Hh 
pathway activity after stimulation with a fixed dose of Shh ligand following priming treatments 
with different concentrations of FA (red curve) or when pathway activity was stimulated by 
expressing a constitutively active SmoM2 variant (blue curve). All Gli-luciferase assay samples 
were replicated four times. The qRT-PCR in (B) was performed in triplicate. Data represent 
mean (± S.D.). (G) Schematics showing the structures of Bodipy-Cyc and Smo. Critical sites in 
the 6
th and 7
th transmembrane domains of Smo, that are likely important for direct interactions 26 
 
are highlighted by rectangles. (H) Representative merged images from Bodipy-Cyc competition 
assays. Transfected cells can be identified by co-labeling with nuclear localized tagRFPT.  (I) 
Quantification of Bodipy-Cyc fluorescence signal: each data point represents values from 50-100 
transfected cells. The controls, including data from a parental plasmid(pCIT), Smo and SmoM2 
expressing cells were displayed as the dashed lines. Mean (± S.D.) was calculated from four 
replicate samples. Scale bar: 10µ m.  
 
Fig. 3. Drug-drug interaction between FA and GDC0449. (A) GDC0449 dose-dependent 
inhibition of Shh stimulated Hh pathway activity in the presence or absence of 10 µ M FA, or 
SmoM2 expressing cell lines. (B) Representative images of Smo::EGFP/Ivs::tagRFPT cells 
treated with GDC0449 and Shh in the presence or absence of 10 µ M FA. GDC0449 was co-
applied at 111nM and 1,111nM respectively with Shh and Shh+FA.  (C) Relative Smo::EGFP+ 
cilium count of GDC0449’s dose-dependent inhibition of Shh-ligand stimulated accumulation of 
ciliary Smo in the presence or absence of 10 µ M FA. Measurements were performed in 
quadruplicate. Several hundred cells were analyzed in each sample to assess the accumulation of 
Smo in the PC from data in (B). Data plotted are mean (± S.D.). Scale bar: 5 µm. 
 
Fig.4.  FA modulates proliferation of cerebellar granule-cell neural progenitors (CGNP). CGNP 
proliferation was quantified based on percentage of pH3 positive cells. Representative images 
and measurements were shown for FA dose dependent modulation of CGNP proliferation (A-B), 
promotion of Shh stimulated NP proliferation by 10 µ M FA(C-D), and GDC0449 dose-
dependent inhibition of Shh stimulated CGNP proliferation in the presence or absence of 10 µ M 
FA(E-F). GDC0449 was applied at 100nM in (E). Mean (± S.D.) was calculated from four 27 
 
replicate samples each containing over a thousand cells. *p=0.0003(t-test). #p<0.0001(t-test). 
Scale bar: 20µm. 
 
Fig.5. Bud inhibits Hh pathway activity induced by various stimuli and does not compete with 
Cyc for binding Smo. (A) The chemical structure of Bud. (B-C) representative images (B) and 
quantification of Smo ciliary localization (C) in Smo::EGFP/Ivs::tagRFPT cells treated with Shh 
and varying concentrations of Bud. (D) Measurement of Hh pathway activity in cells treated with 
Bud only or Bud followed by Shh. (E) Dose dependent inhibition of Hh pathway activity by Bud 
on Shh or SAG treatment, 50nM or 1µ M, respectively. (F-G) representative images (F) and 
quantification of Smo::EGFP or SmoM2::EGFP ciliary intensity (G) from cells treated with Bud. 
Bud was used at 22.2µ M in (F). (H) Bud's dose dependent inhibition of Hh pathway activity 
induced by overexpression of wildtype Smo and SmoM2  respectively. (I) Bud's dose dependent 
inhibition of Hh pathway activity induced by Shh ligand in Smo-/- cells transfected with 
constructs expressing wildtype Smo and SmoD473H  respectively. (J-K) representative images 
(J) and quantification of Smo::EGFP or SmoD473H::EGFP ciliary intensity (K) from cells 
treated with Bud. (L) Measurement of Hh pathway activity in suFU-/- cells treated with Bud and 
FA respectively. DMSO and SAG were used as negative control and GANT61 was positive 
control. (M-N) representative images (M) and quantification of Bodipy-Cyc intensity in Smo 
expressing cos7 cells (N) treated with Bodipy-Cyc and Bud. Vehicle was used for comparison. 
Bud was used at 200µ M in (M). All quantitative data represent mean (± S.D.) from either 
quadruplicated samples (imaging assays) or triplicate experiments (Gli-luciferase assays).  
Quantifications of ciliary localization involved over a thousand cells per sample whereas 50-100 28 
 
Smo expressing cells were analyzed in each treatment for Bodipy-Cyc competition assay. Scale 
bar: 5µ m. 
 
Fig. 6. GDC0449 and Bud combinatorially inhibit Smo-directed Hedgehog signaling. (A-B) 
Quantification of Smo ciliary localization (A) and representative images (B) of 
Smo::EGFP/Ivs::tagRFPT cells treated with GDC0449 and Shh in the presence or absence of 10 
µ M Bud. In (A), GDC0449 was co-applied at 1.6nM with Shh and Shh+Bud respectively.   (C) 
GDC0449 dose-dependent inhibition of Shh stimulated Hh pathway activity in the presence or 
absence of 10 µ M Bud. Data plotted are mean (± S.D.) from four biological replicates (B) 
analyzing over a thousand of cells or three biological replicates(C).  Scale bar: 5 µ m. 
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Supplementary Figure Legends: 
 
Fig. S1(Related to Fig.1). A high content screen for compounds driving Smo ciliary tranlocation. 
(A) A 500nM solution of the small molecule Smo agonist SAG was serially diluted in low serum 
medium Smo::EGFP/Ivs::tagRFPT cells were treated with varying concentrations of SAG.  Here 
and elsewhere, the Ivs::tagRFPT images were shifted leftwards by 5 pixels to show both Smo 
and Ivs signals in merged images. Scale bar: 5µ m. (B) Multi-parametric quantification of data 
sets in the high content assay: mean (± S.D.) from duplicate experiments are presented. (C)A 
15µ M Cyc solution was serially diluted in low serum medium and introduced to 
Smo::EGFP/Ivs::tagRFPT cells. Scale bar: 10µ m. (D) Multi-parametric quantifications of data: 
mean from duplicate experiments. (E) A 200µ M solution of FKL was serially diluted in low 
serum medium and applied to Smo::EGFP/Ivs::tagRFPT cells. Note the lengthened cilium of 
treatment with FKL evident by lengthened Ivs::tagRFPT domain.  Scale bar: 10µ m. (F) Multi-
parametric quantification of data sets: mean (± S.D) from four replicates. (G) A Plot of relative 
Smo::EGFP+ cilium count normalized to cell number for putative agonist screen. Each dot 
represents the measurement of over a thousand cells in each well. Compound libraries were 
assayed at 10µ M. SANT-1 and SAG were used at 1µ M and Cyc at 10µ M. (H) The chemical 
structure of LY294002. (I) Representative images of Smo::EGFP/Ivs::tagRFPT cells treated with 
30µ M LY294002 in comparison with DMSO vehicle only. Scale bar: 10µ m. (J) Quantification 
of Smo::EGFP positive cilia upon treatment with varying concentrations of LY294002 (red) and 
dose dependent inhibition of Shh ligand driven pathway activity by LY294002 (blue). (K) High 
content quantification of various parameters of treatment with varying concentrations of 
LY294002.  Means (± S.D) from four replicates were presented. (L) Structures of all 37 
 
glucocorticoids (in alphabetical order) demonstrated to promote Smo ciliary accumulation. (M) 
High content image analyses of Smo::EGFP/Ivs::tagRFPT cells treated with a different 
concentrations of FA. Measurements were performed in quadruplicate scoring several hundred 
cells in each sample. Data display mean values (± S.D). (N) Representative images of 
immunofluorescence of cilium markers including acetylated tubulin(acet-tub), detyrosinated α- 
tubulin(glu-tub), and Arl13b, and quantification of Arl13b measurements upon treatment with 
FA or the vehicle. (O) Wnt signaling activity as measured by Top-flash signal was not affected 
when FA was applied alone, simultaneously with Wnt3a ligand or whenreporter cells were pre-
treated with FA prior to Wnt3a ligand addition. Measurements were performed in quadruplicate. 
Data display the mean (± S.D.). 
 
Fig. S2(Related to Fig.2). Analyses of Smo ciliary accumulation induced by overexpression or 
FA. (A) Comparison of the dose-response required for activating the Hh pathway when over-
expressing Smo (red curve) or GFP (green curve) in reporter cells. Experiments were performed 
in quadruplicate. Data display the mean (± S.D.). (Inset) A representative image of a Smo over-
expressing cell line shows Smo accumulation in the PC in the absence of ligand. Scale bar: 10 
µm. (B) Representative images taken immediately, 8hours, and 24 hours after FA(10 µ M) 
withdrawal. (C) Time lapse plots of the fluorescent intensity of Smo::EGFP and Ivs::tagRFPT at 
the PC following FA(10 µ M)  withdrawal. Data display the mean (± S.D.) calculated from four 
repeats measuring several hundred cells in each sample. Scale bar: 5 µ m. 
 (D)Measurements of Gli-luciferase activity of wildtype and Smo-/- MEF cells treated with FA 
and TA respectively. Data represent mean (± S.D.) of triplicated samples. P values from student t 
tests comparing with DMSO treated controls were labeled. “n.s.” stands for “non-significance”. 38 
 
(E) Graphs of dose dependent reduction of FA driven Smo accumulation within the PC on 
increasing levels of SANT-1 and GDC0449. Mean (± S.D.) of relative number of Smo+ PC 
calculated from analysis of several hundred cells in quadruplicate treatments. (F) Representative 
images. Scale bar: 5 µm. 
 
Fig. S3(Related to Fig.3). FA confers resistance to Hh pathway inhibition by the Smo 
antagonists Cyc and SANT-1. (A-B) Cyc (A) or SANT-1(B) mediated dose dependent inhibition 
of Shh ligand induced Hh pathway activation in the presence or absence of 10 µ M FA. (C) 
SANT-1 mediated dose-dependent inhibition of Smo accumulation at the PC in response to Shh 
ligand stimulation in the presence or absence of 10 µ M FA. (D) Representative images 
quantified in (C).  SANT-1 was applied at 370nM.  Measurements represent several hundred 
cells in quadruplicate samples. Data plotted display the mean (± S.D.). Scale bar: 5 µ m. 
 
Fig. S4(Related to Fig.1-3). Characterization of TA. (A) Significant activation of the Hh 
pathway only at high doses of TA, measured by a Gli responsive luciferase reporter activity in 
NIH/3T3 cells. * P=0.005 and **P < 0.0001 (t-test), comparing with DMSO. (B) Measurement 
of Hh pathway activity in cells treated simultaneously with a fixed concentration of TA (10µ M) 
and different concentrations of Shh ligand Treatment with Shh ligand and DMSO were used for 
comparison. (C-D) Representative images(C) and quantification of Bodipy-Cyc fluorescence 
signal(D) from competition assays. The controls, including data from a parental plasmid(pCIT) 
and competition by SAG or Cyc, were displayed. Mean (± S.D.) was calculated from four 
replicate samples. Scale bar: 10µ m. (E) GDC0449 dose-dependent inhibition of Shh stimulated 
Hh pathway activity in the presence or absence of 10 µ M TA. (F) Representative images of 39 
 
Smo::EGFP/Ivs::tagRFPT cells treated with GDC0449 and Shh in the presence or absence of 10 
µ M TA. GDC0449 was co-applied at 15.6nM with Shh+DMSO or Shh+TA.  (G) Relative 
Smo::EGFP ciliary intensity of GDC0449’s dose-dependent inhibition of Shh induced Smo 
ciliary accumulation in the presence or absence of 10 µ M TA. Measurements were performed in 
quadruplicate. Several hundred cells were analyzed in each sample to assess the accumulation of 
Smo in the PC. Data plotted are mean (± S.D.). Scale bar: 5 µm. All Gli-luciferase assay samples 
corresponding to this figure were replicated three times.  
 
Fig. S5(Related to Fig.5). Analyses of GC Smo antagonists, Cic and Bud. (A) Cic structure. (B) 
representative images of Shh treated Smo::EGFP/Ivs::tagRFPT cells with DMSO or Cic at 30µ M. 
Scale bar: 5µm. (C) Quantification of Smo ciliary localization of cells treated with Shh and 
various doses of Cic.  Measurements represent several hundred cells in quadruplicate samples. 
Data plotted display the mean (± S.D.). (D) Cic dose-dependent inhibition of Hh pathway activity 
measured by a Gli responsive luciferase reporter activity in NIH/3T3 cells. Data plotted display 
the mean (± S.D.) of triplicate samples. (E) Representative images of Smo::EGFP/Ivs::tagRFPT 
cells treated with 100µ M Bud and 5µM  Cyc or varying doses of SAG. DMSO was a vehicle 
control for comparison. Scale bar: 5µm. (F) Quantification of Bud's dose-dependent inhibition of 
Smo::EGFP ciliary intensity induced by SAG or Cyc.  Measurements represent several hundred 
cells in quadruplicate samples. Data plotted display the mean (± S.D.). (G) Wnt signaling activity 
in a Top-flash reporter assay was not affected when Bud was applied alone, simultaneously with 
Wnt3a ligand or by pre-treating reporter cells prior to Wnt3a ligand addition. Measurements 
were performed in quadruplicate. Data display the mean (± S.D.). (H and J) Representative 
images of Smo::EGFP and SmoM2::EGFP overexpressing cells treated with 370nM SANT-1 (H) 40 
 
or 370nM GDC0449 (J). DMSO was used as a control for comparison. Scale bar: 5µ m. (I and K) 
Quantification of ciliary intensity of Smo::EGFP and SmoM2::EGFP for cells treated with 
varying concentrations of SANT-1(I) or GDC0449(K).  Data plotted display the mean (± S.D.) 
from triplicate experiments. (L) Representative images of Smo::EGFP and SmoM2::EGFP 
overexpressing cells treated with 100µ M Cic. DMSO was used as a control for comparison.  
Both Ivs::tagRFPT and acetylated tubulin (acet-tub) were examined as markers enriched in the 
PC. Scale bar: 5µ m. (M-O) Quantification of Smo::EGFP and SmoM2::EGFP ciliary intensity 
(M),  Ivs::tagRFPT ciliary intensity (N), and Ivs::tagRFPT positive cilium count (O).  
Measurements represent several hundred cells in quadruplicate samples. Data plotted display the 
mean (± S.D.). (P) High content quantification of Smo::EGFP/Ivs::tagRFPT cells treated with 
Shh and varying concentrations of Bud. Measurements represent several hundred cells in 
quadruplicate samples. Data plotted display the mean (± S.D.). (Q)Comparative analysis of 
Arl13b::tagRFPT and acet-tub in the PC of cells treated with 100µ M Bud or DMSO vehicle. 
Scale bar: 5µm. (R) Quantitative analyses of Arl13b::tagRFPT positive primary cilia upon Bud 
treatment. Measurements represent several hundred cells in quadruplicate samples. Data plotted 
display the mean (± S.D.). (S) Measurements of Gli-luciferase activity in Smo-/- MEF cells 
tranfected with a plasmid expressing GFP, wildtype Smo, or SmoD473H, and treated with BSA 
or Shh. (T) Dose reponse measurements of GDC0449 for Shh induced Gli-luciferase activity in 
Smo-/- MEF cells expressing wildtype Smo or SmoD473H. (U-V) representative images(U) and 
dose response measurements of ciliary EGFP intensity that is fused to either wildtype Smo or 
SmoD473H and expressed in 3T3 cells, upon treatment with GDC0449. 
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